

JAGSONPAL PHARMACEUTICALS LIMITED Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax:0091-11-26498341, 26494708, Phone:0091-11-26494519-24 CIN No. L74899DL1978PLC009181

JPL/SEC/RES-NOT1/4

Date: November 14, 2018,

The National Stock Exchange of India Ltd.

Exchange Plaza,

Bandara-Kurla Complex

Bandra (E), Mumbai - 400 051.

Ph. 022-26598452

The Bombay Stock Exchange Limited Pherozebhoy Jeejeebhoy Tower

Dalal Street,

Mumbai - 400 001

Ph. 022-22721234

Symbol: JAGSNPHARM

Scrip Code: 507789

SUB: SUBMISSION OF UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30.09.2018 UNDER REGULATION 33 OF SEBI LODR 2015 (STANDALONE) ALONG WITH LIMITED REVIEW.

Dear Sir,

Please find enclosed herewith **Un-audited Standalone Financial Results** for the 2nd quarter / half year ended 30th September, 2018 duly approved by the Board at its meeting held on 14th November, 2018.

The Limited Review on the **Un-audited Standalone Financial Results** for the Quarter ended 30th September, 2018 in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulation 2015 is enclosed herewith.

Thanking you.

Yours faithfully,

for JAGSONPAL PHARMACEUTICALS LIMITED

RKAPOOR

COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl.: As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regol Office: T-2100, Shahpur Jai, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

Statement of Standalone Unaudited Financial Results for the Quarter ended 30.09.2018 and Half Year Ended 30.9.2018

Rs. in lacs

		Standaione				12 Months	
	Particulars		Quarter Ended		Half Year Ended		Year Ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018		31.03.2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
a	Gross Sales/Revenue from Operations	4412.49	4240.40	2890.68	8652.89	5587.46	12660.42
b	Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from operations	4412.49	4240.40	2890.68	8652.89	5587.46	12660.42
2	Other Income	18.30	8.79	17.21	27.09	29.36	45.68
3	Total Income [1+2]	4430.79	4249.19	2907.89	8679.98	5616.82	12706.10
4	Expenses						
a	Cost of materials consumed	990.99	850.56	732.91	1841.55	1808.10	2688.60
b	Purchases of stock-in-trade	208.53	316.36	964.66	524.89	2117.98	3830.84
C.	Changes in inventories of finished goods, work in progress and Stock in trade	766.19	968.37	-146.34	1734.56	-972.79	-408.44
d.	Excise Duty	0.00	0.00	0.00	0.00	7.13	7.13
е.	Employee benefits expenses	1264.76	1062.42	1104.97	2327.18	2063.63	4187.97
f.	Finance Cost	19.74	17.08	19.15	36.82	37.78	65.72
g.	Depreciation and amortisation expense	24.99	25.40	1.89	50.39	28.36	31.98
h.	Other expenses	934.35	918.09	625.12	1852.44	1343.17	3464.97
	Total expenses	4209.55	4158.28	3302.36	8367.83	6433.36	13868.77
5	Profit before exceptional items and taxes (3-4)	221.24	90.91	-394.47	312.15	-816.54	-1162.67
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit before tax [5-6]	221.24	90.91	-394.47	312.15	-816.54	-1162.67
8	Tax expense	44.25	18.18	-9.13	62.43	-9.13	-7.61
9	Net Profit for the period [7-8]	176.99	72.73	-385.34	249.72	-807.41	-1155.06
10							
A	(i) Items that will not be classifies to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
v	(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
11	Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00	0.00
12	Total Comprehensive Income [9+11]	176.99	72.73	-385.34	249.72	-807.41	-1155.06
13	Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
14	Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)						
a .	Basic (Rs.)	0.68	0.28	-1.47	0.95	-3.08	-4.41
b.	Diluted (Rs.)	0.68	0.28	-1.47	0.95	-3.08	-4.41

Notes

- 1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 14, 2018.
- 2) In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 3) Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- 4) The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 5) According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, revenue for the corresponding half yearly ended 30-09-2018 and year ended March 31,2018 were reported inclusive od Excise Duty. The Government of India has implemented Goods and Service Tax ("gst") from July 01, 2017 replacing Excise Duty, Service Tax and various indirect taxes. AS per Ind AS 18, the revenue for the half yearly ended 30-9-2018, is reported net of GST and is not comparable with previous reported half year.
- 6) Provision for taxation includes provision for current tax.

7) Figures for the quarter ended 31st March 2018 are balancing figures between the audited figures in respect of full financial year ended 31st March 2018 and published figure for the half year ended 305 2017

Place: New Delhi

Date: 14-11-2018

By Order of the Board

For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar Managing Director

DIN No 00059492




JAGSONPAL PHARMACEUTICALS LIMITED Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-2649(R\$9ñ2fakhs)

CIN No. L74899DL1978PLC009181

State	ement of Assets and Liabilities			
Particulars		As on 30.09.2018 (Unaudited)	As on 31.03.2018 (Audited)	
ASS	SETS			
1	Non-current assets			
	(a) Property, Plant and Equipment	2099.97	2128.71	
	(b) Capital Work-in-Progress	142.59	97.92	
	(c) Goodwill	3.00	3.00	
	(d) Intangible assets under development	206.27	206.27	
	(e) Financial assets			
· • • • • • • • • • • • • • • • • • • •	(i) Investments	0.05	0.05	
	(f) Other non-current assets	1111.62	1084.23	
	Total non-current assets	3563.50	3520.18	
2	Current assets	·		
	(a) Inventories	3266.53	5143.38	
	(b) Financial assets			
	(i) Trade receivables	2554.32	2515.36	
	(ii) Cash and Cash equivalents	73.84	52.23	
	(iii) Bank balances other than (ii) above	2798.96	1399.01	
	(c) Other current assets	538.31	351.32	
	Total current assets	9231.96	9461.30	
	TOTAL ASSETS	12795.46	12981.48	

	10. The second of the second o	A TANAN TANA
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	8744.49	8526.29
Total Equity	10054.39	9836.19
LIABILITIES		
1 Non-current liabilities		
(a) Deferred tax liabilities (Net)	318.53	318.52
(b) Non current borrowings	0.00	0.00
Non-current liabilities	318.53	318.52
2 Current Liabilities		
(a) Financial Liabilities		
(i) Trade payables	935.82	909.26
(II) Short term borrowings	603.64	830.05
(b) Other current liabilities	311.28	578.10
(c) Provision for tax	571.80	509.36
Total current liabilities	2422.54	2826.77
Total Liabilities	2741.07	3145.29
TOTAL - EQUITY AND LIABILITIES	12795.46	12981.48

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953



H. L. BANSAL & CO

Chartered Accountants

The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049

- 1. We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter & half year ended September 30, 2018 which are included in the accompanying Statement of Standalone Financial Results for the Quarter ended September 30, 2018 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialed by us for identification purposes. The Statement is the responsibility of the Company's management and is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent and are in accordance with the Companies (Indian Accounting Standards) rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
- 3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not qualified in respect of these matters.

For H.L. Bansal & Co.

Firm Registration Number: 08563N

Chartered Accountants

H. L. Bansal Propreiter

Membership Number 086990